Denali Therapeutics Inc. (DNLI) Financial Statements
Denali Therapeutics Inc. (DNLI) reported trailing twelve-month revenue of $3.6M (up 157.9% year on year) and net income of -$511.5M as of 2026-06-30, according to EquiReason's reading of its SEC filings. Free cash flow over the same period: -$437.5M.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
DNLIDenali Therapeutics Inc.Follow DNLI — free
—
Price chart with a free account
- Market cap
- 2.9B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 4 Nov, in 11 days
Fiscal-year columns end in the month shown. The current fiscal year appears once its annual report is filed; until then TTM = the last four reported quarters, to Jun 26.
| Line | FY2018 Dec 18 | FY2019 Dec 19 | FY2020 Dec 20 | FY2021 Dec 21 | FY2022 Dec 22 | FY2023 Dec 23 | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.13 | 0.03 | 0.34 | 0.05 | 0.11 | 0.33 | 0.00 | 0.00 | 0.00 | |
| Research & development | 0.14 | 0.19 | 0.21 | 0.27 | 0.36 | 0.42 | 0.40 | 0.42 | 0.40 | |
| Operating income | -0.05 | -0.21 | 0.06 | -0.30 | -0.34 | -0.20 | -0.49 | -0.56 | -0.54 | |
| Pre-tax income | -0.04 | -0.20 | 0.07 | -0.29 | -0.33 | -0.15 | -0.42 | -0.51 | — | |
| Income tax | — | -0.00 | 0.00 | -0.00 | 0.00 | 0.00 | 0.00 | 0.00 | — | |
| Net income | -0.04 | -0.20 | 0.07 | -0.29 | -0.33 | -0.15 | -0.42 | -0.51 | -0.51 | |
| Diluted EPS ($) | -0.39 | -2.07 | 0.63 | -2.39 | -2.60 | -1.06 | -2.57 | -2.97 | -2.84 | |
| Diluted shares (bn) | — | — | 0.113 | 0.122 | 0.126 | 0.137 | 0.164 | 0.173 | — |
USD billions · SEC XBRL
Denali Therapeutics Inc. — questions
- What is Denali Therapeutics Inc.'s revenue?
- $3.6M over the twelve months to 2026-06-30, up 157.9% year on year, from its 10-Q and 10-K filings.
- What is Denali Therapeutics Inc.'s net income?
- -$511.5M over the twelve months to 2026-06-30.
- What is Denali Therapeutics Inc.'s free cash flow?
- -$437.5M over the twelve months to 2026-06-30.
- What are Denali Therapeutics Inc.'s diluted earnings per share?
- $-2.84 over the twelve months to 2026-06-30.
Every figure on this page comes from Denali Therapeutics Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.